Armata Pharmaceuticals Inc (ARMP)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Armata Pharmaceuticals Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 11 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 4.50 $ — 17% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
NeutralGeprüft am 10.07.2026 gegen den Geschäftsbericht (10-K) 2025 (eingereicht 25.03.2026) und den jüngsten Quartalsbericht (10-Q) zum 31.03.2026 (eingereicht 13.05.2026): In den ausgewerteten SEC-Filings von Armata Pharmaceuticals findet sich kein wesentlicher KI-Bezug. Armata ist ein klinisches Biotech-Unternehmen, das Bakteriophagen-Therapien gegen antibiotika-resistente Bakterien entwickelt (Leitkandidaten AP-PA02 und AP-SA02); künstliche Intelligenz ist weder Umsatzquelle noch als operatives Werkzeug (z. B. KI-gestützte Wirkstoffsuche) beschrieben. Die einzigen Erwähnungen sind generische Boilerplate: eine Aufzählung möglicher Zukunftsrisiken in den Forward-Looking-Statements des 10-K („the effects of artificial intelligence on our business and the industry as a whole“) sowie ein allgemeiner Risikofaktor, dass der breitere Einsatz von KI durch die Firma, Dritte und Wettbewerber neue operative Risiken schaffen könne. Nach der Vorrang-Regel begründet solche branchenweite Boilerplate weder „bedroht“ (kein konkretes KI-Geschäftsrisiko fürs eigene Phagen-Modell) noch „nutzt“ oder „verkauft“ — Einstufung damit „neutral“.
View the full file — quotes, sources, reviewed filings
Filings Reviewed: 10-K 2026-03-25 · 10-Q 2026-05-13
Rated on July 10, 2026 · How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 288.9% above the current price.
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Next Reporting Date
- Expected Earnings per Share
- -0.48 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.07 | – | 1 | -19.20 | 210.50 | -8 | -8 |
| 2025: Q1 | -0.18 | – | 1 | -49.20 | -1,330.10 | -8 | -8 |
| 2025: Q2 | -0.44 | -281.30 | 2 | – | -751.30 | -7 | -7 |
| 2025: Q3 | -0.73 | – | 1 | -61.00 | -2,301.60 | -4 | -5 |
| 2025: Q4 | -3.39 | -4,880.70 | 1 | -12.10 | -11,456.00 | -7 | -7 |
| 2026: Q1 | -3.14 | – | 1 | 60.70 | -14,619.30 | -6 | -6 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Armata Pharmaceuticals, Inc. ist ein Biotechnologieunternehmen in der klinischen Phase, das sich auf die Entwicklung zielgerichteter Bakteriophagen-Therapeutika gegen antibiotikaresistente Infektionen weltweit konzentriert.
| Employees | 61 |
|---|---|
| Headquarters | Los Angeles, CA |
| Website | armatapharma.com |
| IPO Date | 9. Mar 2011 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Deborah L. Birx M.D. | CEO & Director | 1957 |
| David D. House | Senior VP of Finance & Principal Financial Officer | 1984 |
| Pierre Kyme Ph.D. | Chief Business Officer | 1978 |
| Peter Hubbard | Vice President of Operations | – |
| Bani Tchekanova Ph.D. | Head of Regulatory Strategy & Operations | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 10. Jul 2026 | Birx Deborah | Chief Executive Officer | Other | 14,041 | 4.26 | 59,815 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.